EN
Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy
Abstract
Colorectal cancer (CRC) is one of the most prevalent cancer types worldwide, and the development of new targets in treatment approaches is of critical importance. In recent years, there has been a growing interest in the role of endoplasmic reticulum (ER) stress in the development of CRC and the effectiveness of cancer treatments. ER stress is a process linked to the disruption of cellular homeostasis and the activation of diverse biochemical pathways. Increased ER stress can influence cell fate by activating either adaptive pathways that promote survival or apoptotic pathways that lead to cell death. Proteins such as X-box binding protein-1 spliced form (XBP-1s), activating transcription factor 4 (ATF4), and activating transcription factor 6 (ATF6) are predominantly implicated in the adaptive response, whereas CCAAT/ enhancer-binding protein (C/EBP) homologous protein (CHOP) and phospho-apoptosis signal regulating kinase 1 (p-ASK1) are primarily associated with the apoptotic response. Nonetheless, the functional roles of these proteins may vary depending on the specific conditions. The purpose of this review is to evaluate studies primarily conducted over the past decade, focusing specifically on the effects of existing drugs and candidate molecules used in CRC treatment on ER stress proteins, emphasising their role in reducing drug resistance and enhancing the efficacy of treatment. Considering the articles reviewed in this compilation, it is concluded that the suppression of the adaptive pathway [inositol requiring enzyme - 1α (IRE-1α)/XBP-1s ] through inhibitors and the prolongation of ER stress to activate apoptotic proteins (CHOP, p-ASK1) can enhance drug efficacy and reverse drug resistance. This approach is considered a novel and effective therapeutic strategy for CRC.
Keywords
References
- Abbasi, S., Rivand, H., Eshaghi, F., Moosavi, M. A., Amanpour, S., McDermott, M. F., & Rahmati, M. (2023). Inhibition of IRE1 RNase activity modulates tumor cell progression and enhances the response to chemotherapy in colorectal cancer. Medical Oncology, 40(9), 247. https://doi.org/10.1007/s12032-023-02105-7 google scholar
- Ahmad, R., Singh, J. K., Wunnava, A., Al-Obeed, O., Abdulla, M., & Srivastava, S. K. (2021). Emerging trends in colorectal cancer: Dysregulated signaling pathways. International Journal of Molecular Medicine, 47(3), 14. https://doi.org/10.3892/ ijmm.2021.4847 google scholar
- Alnuqaydan, A. M., Rah, B., Almutary, A. G., & Chauhan, S. S. (2020). Synergistic antitu-mor effect of 5-fluorouracil and withaferin-A induces endoplasmic reticulum stress-mediated autophagy and apoptosis in colorectal cancer cells. American Journal of Cancer Research, 10(3), 799-815. google scholar
- B'chir, W., Chaveroux, C., Carraro, V., Averous, J., Maurin, A.-C., Jousse, C., Muranishi, Y., Parry, L., Fafournoux, P., & Bruhat, A. (2014). Dual role for CHOP in the crosstalk between autophagy and apoptosis to determine cell fate in response to amino acid deprivation. Cellular Signalling, 26(7), 1385-1391. https://doi.org/10.1016/ j.cellsig.2014.03.009. google scholar
- Biller, L. H., & Schrag, D. (2021). Diagnosis and treatment of metastatic colorectal cancer: a review. Jama, 325(7), 669-685. https://doi.org/10.1001/jama.2021.0106 google scholar
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229-263. https://doi.org/10.3322/caac.21834 google scholar
- Burness, C. B., & Duggan, S. T. (2016). Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer. Drugs, 76(14), 1393-1402. https://doi.org/10.1007/s40265-016-0633-9 google scholar
- Chen, W., Lian, W., Yuan, Y., & Li, M. (2019). The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress. Cell Death & Disease, 10(8), 600. https://doi.org/10.1038/s41419-019-1824-6. google scholar
Details
Primary Language
English
Subjects
Pharmaceutical Biochemistry
Journal Section
Review
Authors
Publication Date
May 7, 2025
Submission Date
October 27, 2024
Acceptance Date
January 8, 2025
Published in Issue
Year 2025 Volume: 55 Number: 1
APA
Arcan, G. G., & Aksoy Sağırlı, P. (2025). Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy. İstanbul Journal of Pharmacy, 55(1), 119-130. https://doi.org/10.26650/IstanbulJPharm.2025.1574537
AMA
1.Arcan GG, Aksoy Sağırlı P. Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy. iujp. 2025;55(1):119-130. doi:10.26650/IstanbulJPharm.2025.1574537
Chicago
Arcan, Gülşah Gamze, and Pınar Aksoy Sağırlı. 2025. “Up to Date: Endoplasmic Reticulum Stress-Targeted Colorectal Cancer Therapy”. İstanbul Journal of Pharmacy 55 (1): 119-30. https://doi.org/10.26650/IstanbulJPharm.2025.1574537.
EndNote
Arcan GG, Aksoy Sağırlı P (May 1, 2025) Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy. İstanbul Journal of Pharmacy 55 1 119–130.
IEEE
[1]G. G. Arcan and P. Aksoy Sağırlı, “Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy”, iujp, vol. 55, no. 1, pp. 119–130, May 2025, doi: 10.26650/IstanbulJPharm.2025.1574537.
ISNAD
Arcan, Gülşah Gamze - Aksoy Sağırlı, Pınar. “Up to Date: Endoplasmic Reticulum Stress-Targeted Colorectal Cancer Therapy”. İstanbul Journal of Pharmacy 55/1 (May 1, 2025): 119-130. https://doi.org/10.26650/IstanbulJPharm.2025.1574537.
JAMA
1.Arcan GG, Aksoy Sağırlı P. Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy. iujp. 2025;55:119–130.
MLA
Arcan, Gülşah Gamze, and Pınar Aksoy Sağırlı. “Up to Date: Endoplasmic Reticulum Stress-Targeted Colorectal Cancer Therapy”. İstanbul Journal of Pharmacy, vol. 55, no. 1, May 2025, pp. 119-30, doi:10.26650/IstanbulJPharm.2025.1574537.
Vancouver
1.Gülşah Gamze Arcan, Pınar Aksoy Sağırlı. Up to date: Endoplasmic reticulum stress-targeted colorectal cancer therapy. iujp. 2025 May 1;55(1):119-30. doi:10.26650/IstanbulJPharm.2025.1574537